Convergent Therapeutics Announces $90 Million Series A Financing To Advance The Clinical Development Of Radiopharmaceuticals For The Treatment Of Prostate Cancer And Other Solid Tumors

May 03, 2023•over 2 years ago

Amount Raised

$90 Million

Round Type

series a

CambridgeBiotechnologyHealth CareTherapeutics

Investors

InvusRa Capital ManagementOrbi Med

Description

Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals for the treatment of cancer, today announced the completion of a $90 million Series A financing, led by OrbiMed and RA Capital Management with participation from Invus. The financing will support the development of a pipeline of novel radioantibodies, including its lead program with CONV01-α, for the treatment of advanced prostate cancer.

Company Information

Company

Convergent Therapeutics

Location

Cambridge, Massachusetts, United States

About

Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.

Related People

5 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends